|Day Low/High||78.51 / 79.50|
|52 Wk Low/High||77.92 / 120.37|
Investors shouldn't give up on Gilead's Hep. C drug, Cramer says.
Gilead (GILD) stock was down in pre-market trading on Tuesday after Leerink cut its rating on shares to 'market perform.'
Here are Tuesday's top research calls, including upgrades for AutoZone and Eli Lilly, and downgrades for J.M. Smucker and Toll Brothers.
Stocks end Monday's session sharply lower as Wall Street grows restless ahead of the first presidential debate.
Driving sector performance are a recent series of mergers and acquisitions, including Horizon Pharma's purchase of Raptor Pharmaceutical Corp. Then there's the political boost...
Stocks hold near session lows by mid-afternoon Monday as Wall Street grows restless ahead of the first presidential debate.
Leerink said on Monday that Gilead (GILD) could see a 'slight uplift' in its research and development strategy on partner Galapagos' (GLPG) positive drug trial results.
Stocks are lower Monday as Wall Street's attention shifts to the looming presidential debate from central bank policy.
Jim Cramer shares his views on why the market is hated and oil charades from the producing nations.
Citigroup analysts say recent IMS Health data show that Gilead (GILD) Hepatitis C drug sales have grown quarter-over-quarter.
Apart from the Fed, there are other factors that make investors nervous.
Gilead Sciences' (GILD) NASH liver disease pipeline is "very attractive," Gabelli said in an analyst note on Thursday.
The Irish drugmaker isn't likely done making deals, even though it just made two, and it could take a look at Alder Biopharmaceuticals next, analysts believe.
Gilead Sciences, Inc. (Nasdaq:GILD) today announced that the company is stopping its combined Phase 2/3 clinical study of GS-5745, an investigational anti-MMP9 antibody, among patients with moderately to severely active...
Gabelli analysts say Gilead Sciences (GILD) could be the next possible takeover target by Allergan (AGN), as the company has a 'deep pipeline' of NASH drugs.
Gilead (GILD) stock was climbing Tuesday afternoon after Allergan (AGN) said it would buy Tobira (TBRA).
Shares of Gilead Sciences are surging today. Here's how to trade the stock from here.
Buybacks may alert investors to a great opportunity or worthless paperwork.
Emulate Graham and Buffett with Greenblatt’s 'Magic Formula' screen.
The once-mighty biotech has fallen, but entry opportunities will surface.
Jefferies analysts say Gilead's (GILD) $5 billion debt offering could suggest that the company plans to seek out one or several acquisitions, possibly in the orphan diseases sector.
Gilead Sciences, Inc. (NASDAQ:GILD) today announced the pricing of senior unsecured notes in an aggregate principal amount of $5 billion, in an underwritten, registered public offering, consisting of five tranches: ...
Collectively, the data will give investors a clearer measure of Gilead's internal drug development efforts outside of its core hepatitis C and HIV strengths.
Credit Suisse trimmed its price target on shares of Gilead Sciences (GILD) to $95 in a note on Wednesday.
Gilead is a cheap stock with solid turnaround potential and a healthy dividend.
Gilead Sciences (GILD) CEO John Milligan said on Monday that the company won't rule out a large deal but would prefer a series of smaller ones.
It's been a nasty decline, but if we rally, these three have best charts.
How will biotech stocks end the year? Will FDA approve Sarepta's drug? Will Gilead finally buy another company?